BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25257766)

  • 1. MEK inhibition in non-small cell lung cancer.
    Stinchcombe TE; Johnson GL
    Lung Cancer; 2014 Nov; 86(2):121-5. PubMed ID: 25257766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibitors for the treatment of non-small cell lung cancer.
    Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
    J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK inhibitors under development for treatment of non-small-cell lung cancer.
    Kim C; Giaccone G
    Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
    Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
    Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
    Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
    Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib in the treatment of non-small-cell lung cancer.
    Bernabé R; Patrao A; Carter L; Blackhall F; Dean E
    Future Oncol; 2016 Nov; 12(22):2545-2560. PubMed ID: 27467210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
    Gandara DR; Leighl N; Delord JP; Barlesi F; Bennouna J; Zalcman G; Infante JR; Reckamp KL; Kelly K; Shepherd FA; Mazieres J; Janku F; Gardner OS; Mookerjee B; Wu Y; Cox DS; Schramek D; Peddareddigari V; Liu Y; D'Amelio AM; Blumenschein G
    J Thorac Oncol; 2017 Mar; 12(3):556-566. PubMed ID: 27876675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
    Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
    Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 18. Selumetinib for the treatment of non-small cell lung cancer.
    Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
    Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
    Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
    Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
    Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
    Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.